Leriglitazone Explained

Atc Prefix:	A16
Atc Suffix:	AX23
Synonyms:	Hydroxypioglitazone
Cas Number:	146062-44-4
Pubchem:	4147757
Drugbank:	DB15021
Chemspiderid:	3360070
Chembl:	1267
Unii:	K824X25AYA
Kegg:	D11603
Iupac Name:	5-4-[2-[5-(1-Hydroxyethyl)pyridin-2-yl]ethoxy]phenylmethyl]-1,3-thiazolidine-2,4-dione
C:	19
H:	20
N:	2
O:	4
S:	1
Stdinchi:	1S/C19H20N2O4S/c1-12(22)14-4-5-15(20-11-14)8-9-25-16-6-2-13(3-7-16)10-17-18(23)21-19(24)26-17/h2-7,11-12,17,22H,8-10H2,1H3,(H,21,23,24)
Stdinchikey:	OXVFDZYQLGRLCD-UHFFFAOYSA-N
Smiles:	CC(C1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3)O

Leriglitazone is a PPAR-gamma agonist and metabolite of the glitazone pioglitazone. It is developed for adrenomyeloneuropathy, and other neurodegenerative diseases.^{[1] [2] [3] [4]}

Society and culture

Legal status

In January 2024, the European Medicines Agency (EMA) recommended the refusal of the marketing authorization for leriglitazone (Nezglyal) requested by Minoryx Therapeutics S.L.^[5] In May 2024, the EMA confirmed its recommendation to refuse marketing authorization for leriglitazone. Leriglitazone was intended for the treatment of cerebral adrenoleukodystrophy.

Notes and References

1. Musokhranova . Uliana . Grau . Cristina . Vergara . Cristina . Rodríguez-Pascau . Laura . Xiol . Clara . Castells . Alba A. . Alcántara . Soledad . Rodríguez-Pombo . Pilar . Pizcueta . Pilar . Martinell . Marc . García-Cazorla . Angels . Oyarzábal . Alfonso . Mitochondrial modulation with leriglitazone as a potential treatment for Rett syndrome . Journal of Translational Medicine . 26 October 2023 . 21 . 1 . 756 . 10.1186/s12967-023-04622-5 . 37884937 . 10601217 . 1479-5876 . free .
2. Pizcueta . Pilar . Vergara . Cristina . Emanuele . Marco . Vilalta . Anna . Rodríguez-Pascau . Laura . Martinell . Marc . Development of PPARγ Agonists for the Treatment of Neuroinflammatory and Neurodegenerative Diseases: Leriglitazone as a Promising Candidate . International Journal of Molecular Sciences . 6 February 2023 . 24 . 4 . 3201 . 10.3390/ijms24043201 . 36834611 . 9961553 . 1422-0067 . free .
3. Rodríguez-Pascau . Laura . Vilalta . Anna . Cerrada . Marc . Traver . Estefania . Forss-Petter . Sonja . Weinhofer . Isabelle . Bauer . Jan . Kemp . Stephan . Pina . Guillem . Pascual . Sílvia . Meya . Uwe . Musolino . Patricia L. . Berger . Johannes . Martinell . Marc . Pizcueta . Pilar . The brain penetrant PPARγ agonist leriglitazone restores multiple altered pathways in models of X-linked adrenoleukodystrophy . Science Translational Medicine . 2 June 2021 . 13 . 596 . 10.1126/scitranslmed.abc0555. 34078742 . 235305143 .
4. Pandolfo . Massimo . Reetz . Kathrin . Darling . Alejandra . Rodriguez de Rivera . Francisco Javier . Henry . Pierre-Gilles . Joers . James . Lenglet . Christophe . Adanyeguh . Isaac . Deelchand . Dinesh . Mochel . Fanny . Pousset . Françoise . Pascual . Sílvia . Van den Eede . Delphine . Martin-Ugarte . Itziar . Vilà-Brau . Anna . Mantilla . Adriana . Pascual . María . Martinell . Marc . Meya . Uwe . Durr . Alexandra . Efficacy and Safety of Leriglitazone in Patients With Friedreich Ataxia: A Phase 2 Double-Blind, Randomized Controlled Trial (FRAMES) . Neurology: Genetics . December 2022 . 8 . 6 . e200034 . 10.1212/NXG.0000000000200034. 36524101 . 9747094 .
5. Web site: Nezglyal EPAR . . 25 January 2024 . 3 February 2024.